People: Aegerion Pharmaceuticals Inc (AEGR.O)

AEGR.O on Nasdaq

17.69USD
31 Aug 2015
Change (% chg)

-- (--)
Prev Close
$17.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
558,009
52-wk High
$36.19
52-wk Low
$16.68

Search Stocks

Summary

Name Age Since Current Position

David Scheer

62 2005 Independent Chairman of the Board

Sandford Smith

68 2015 Interim President, Chief Executive Officer, Director

Gregory Perry

54 2015 Chief Financial Officer

Anne Cook

50 2011 Senior Vice President, General Counsel, Secretary

William Andrews

50 2014 Senior Vice President - Business Development

Martha Carter

62 2013 Senior Vice President, Chief Regulatory Officer

David Aubuchon

2015 Chief Accounting Officer

Mark Sumeray

49 2011 Chief Medical Officer

Mary Weger

56 2014 Chief Performance Officer

Sol Barer

68 2011 Independent Director

Antonio Gotto

79 2006 Independent Director

Jorge Plutzky

56 2015 Independent Director

Paul Thomas

59 2011 Independent Director

Anne VanLent

67 2013 Independent Director

Biographies

Name Description

David Scheer

Mr. David I. Scheer is Independent Chairman of the Board of Aegerion Pharmaceuticals Inc., since February 2005. Since 1981, Mr. Scheer has served as Chairman of our Board of Directors since the Company’s formation in February 2005. Since 1981, Mr. Scheer has served as President of Scheer & Company, Inc. (a company that provides venture capital, corporate strategic and transactional advisory services in the life sciences industry). Mr. Scheer serves as the Chairman of the Board of Directors of Achillion Pharmaceuticals, Inc. (a biopharmaceutical company focused on the treatment of hepatitis C virus infection and certain inflammatory diseases) and as Chairman of the Board of Directors of several privately held biotechnology companies. Additionally, Mr. Scheer serves as a member of the Board of Directors of Connecticut United for Research Excellence (CURE), an educational and business advocacy network, and on the Executive Board of the Center for Biomedical Interventional Technologies (CBIT) at Yale University. He has been a co-organizer and/or Chair of a series of life science conferences involving public and global health in collaboration with Yale, and has been a speaker at the annual conferences involving orphan drug innovation for the National Organization for Rare Disorders. the Yale School of Management, and the University of New Haven, and has been an Executive-in-Residence at the Carey Business School at Johns Hopkins University. Mr. Scheer holds an A.B. degree from Harvard College and an M.S. degree in cell, molecular and development biology from Yale University.

Sandford Smith

Mr. Sandford D. Smith is Interim President, Chief Executive Officer, Director of the Company. He was Independent Director of Aegerion Pharmaceuticals Inc., since January 2012. Mr. Smith has served as a member of our Board of Directors since January 2012. Since December 2011, Mr. Smith has served as Founder and Chairman of Global Biolink Partners. Mr. Smith is currently a Managing Director of Tullis Health Investors, which manages a family of funds and investments focusing on the healthcare industry. Prior to joining Tullis Health Investors in January 2012, Mr. Smith served from 1996 until 2011 in various senior and executive management positions at Genzyme Corporation, including most recently as Executive Vice President and President, International Group with responsibility for the commercial activities for Genzyme’s products outside of the U.S. Prior to joining Genzyme, Mr. Smith served from 1986 to 1996 as President and Chief Executive Officer and a Director of Repligen Corporation. Mr. Smith previously held a number of positions with Bristol-Myers Squibb Company from 1977 to 1986, including Vice President of Business Development and Strategic Planning for the Pharmaceutical Group. Mr. Smith currently serves as a director of Cytokynetics, Inc. (a public biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions), Apricus Biosciences, Inc. (a publicly traded biopharmaceutical company focused on advancing innovative medicines in urology and rheumatology), and Neuralstem, Inc. (a publicly traded regenerative medicine company focused on the production of multiple types of central nervous system stem cells for the potential treatment of certain CNS diseases). Mr. Smith serves as a member of the President’s Advisory Board of Brigham and Women’s Hospital in Boston. Mr. Smith holds a B.S. degree from the University of Denver.

Gregory Perry

Mr. Gregory D. Perry is Chief Financial Officer of Aegerion Pharmaceuticals, Inc. Gregory Perry most recently served as chief financial officer of Eleven Biotherapeutics. Prior to joining Eleven Biotherapeutics, Mr. Perry served as the interim chief financial officer of InVivo Therapeutics. Prior to joining InVivo, he served as the executive vice president and chief financial officer of ImmunoGen. Before that, he was the chief financial officer of Elixir Pharmaceuticals. Mr. Perry also previously was senior vice president and chief financial officer of Transkaryotic Therapies. Mr. Perry serves on the board of directors of Ocata Therapeutics. He received a B.A. in Economics and Political Science from Amherst College.

Anne Cook

Ms. Anne Marie Cook is Senior Vice President, General Counsel, Secretary of Aegerion Pharmaceuticals, Inc., since December 5, 2011. From December 2008 to December 2011, Ms. Cook has served as our Senior Vice President, General Counsel and Secretary since December 2011. From December 2008 to December 2011, Ms. Cook was a partner at the law firm Choate Hall & Stewart LLP, where she represented both private and public corporations in the life sciences industry in structuring and negotiating strategic transactions and providing general legal support in connection with the research, development and commercialization of pharmaceutical products. From April 2007 to December 2008, Ms. Cook was a Principal at the law firm Miller Canfield P.L.C. From September 2005 until April 2007, Ms. Cook served as General Counsel and Senior Vice President, Business and Corporate Development, and Secretary of ViaCell, Inc. (a biotechnology company). Prior to joining ViaCell, Ms. Cook spent thirteen years at Biogen Idec Inc., most recently as Vice President, Chief Corporate Counsel. Ms. Cook holds a B.S. degree from Tufts University and a J.D. degree from the University of Notre Dame Law School.

William Andrews

Dr. William Andrews is Senior Vice President, Business Development of Aegerion Pharmaceuticals, Inc. since May 2014.From April 2012 to May 2014, Dr. Andrews served as our Vice President of Medical Affairs, starting and building the Company’s medical affairs function and overseeing medical affairs activities for the launch of JUXTAPID in the United States, Canada, Latin America, and Asia. Prior to joining the Company in 2012, Dr. Andrews served as Vice President of Medical Affairs at Santhera Pharmaceuticals, a company focused on the development and commercialization of innovative therapies for rare diseases. At Santhera, Dr. Andrews built the Global Medical Affairs function and worked on the clinical development of rare disease products. From January 2003 to September 2008, Dr. Andrews served as Director, Senior Director, and Executive Director, Medical Affairs at Sepracor Inc. (renamed Sunovion Pharmaceuticals, Inc. in 2010), a pharmaceutical company focused on the discovery, development and commercialization of Respiratory and CNS therapies. At Sepracor, Dr. Andrews was responsible for overseeing Medical Affairs activities for the Respiratory franchise and served as medical lead of four product launches. Before that, he was Medical Director at ClinQuest, Inc., a clinical research and biopharmaceutical services organization, where he worked on the Clinical Development of multiple innovative therapies and programs. Prior to joining the biopharmaceutical industry over 15 years ago, Dr. Andrews practiced Internal Medicine in Boston at Harvard Vanguard Medical Associates and Brigham and Women’s Hospital. He has also served as Clinical Instructor of Internal Medicine at Harvard Medical School and Attending Physician of Internal Medicine at Brigham and Women’s Hospital. Dr. Andrews received his Doctor of Medicine degree from Yale University School of Medicine, and his Bachelor of Arts degree in Biology from Harvard University.

Martha Carter

Ms. Martha Carter Senior Vice President, Chief Regulatory Officer of Aegerion Pharmaceuticals, Inc. She has served as our Chief Regulatory Officer and Senior Vice President since February 2011. From January 2011 to February 2011, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. (a privately held biopharmaceutical company), and from September 2006 to December 2010, she served as Senior Vice President, Regulatory Affairs and Quality Assurance, at Proteon. In both roles, Ms. Carter was responsible for Proteon’s worldwide regulatory and quality functions. From September 2002 to April 2006, Ms. Carter was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to joining Trine, Ms. Carter was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. Ms. Carter holds a B.A. degree from Northeastern University.

David Aubuchon

Mr. David Aubuchon is an Chief Accounting Officer of the Company. He was Interim Chief Financial Officer of the Company. Prior to joining the Company, Mr. Aubuchon was corporate controller at Ocata Therapeutics since October 2013 and was corporate controller at Inspiration Biopharmaceuticals from July 2012 until December 2012. From 1998 through 2010, Mr. Aubuchon held a series of positions with increasing responsibility at Sepracor (now known as Sunovion Pharmaceuticals), most recently as vice president, corporate controller and chief accounting officer. Additionally, Mr. Aubuchon was previously an auditor at PricewaterhouseCoopers LLP. Mr. Aubuchon holds a B.S. degree from the University of Massachusetts, Amherst and an M.B.A. degree from Babson College. Mr. Aubuchon holds a CPA certificate from the Commonwealth of Massachusetts.

Mark Sumeray

Dr. Mark Sumeray, MD, serves as Chief Medical Officer of Aegerion Pharmaceuticals, Inc., since August 2011. From November 2009 to July 2011, Dr. Sumeray has served as our Chief Medical Officer since August 2011. From November 2009 to July 2011, Dr. Sumeray served as Vice President, Cardiovascular/Metabolics U.S. Medical at Bristol-Myers Squibb (a pharmaceutical company). From December 2004 to November 2009, Dr. Sumeray held various positions at The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President, Medical Business Development, and Vice President Clinical Development and Head of Medical Science. From September 2000 to October 2004, Dr. Sumeray served as worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson. Dr. Sumeray holds a B.S. degree, an M.S. degree in surgery and an M.D. degree from the University College London. Dr. Sumeray is a Fellow of the Royal College of Surgeons, or FRCS, in the United Kingdom.

Mary Weger

Ms. Mary Weger is Chief Performance Officer of Aegerion Pharmaceuticals, Inc. since October 2014. From December 2011 to October 2014, Ms. Weger served as our Senior Vice President, Human Resources. Prior to joining the Company, Ms. Weger was Senior Vice President, Global Clinical Development Strategy & Effectiveness at Celgene Corporation since October 2010. Prior to this appointment, she held the position of Senior Vice President, Global Human Resources at Celgene from May 2002 to October 2010, where she played an instrumental role in helping to build Celgene globally from a company with 150+ employees to a world-wide organization with revenue of over $4 billion and operations in over 30 countries. Prior to joining Celgene, Ms. Weger held positions of increasing responsibility at Kraft Foods Nabisco. She received her Master’s certificate and Black Belt in Six Sigma in 2011 from Villanova University. Ms. Weger also possesses a Master’s degree in Human Resource Management, and has completed the Executive Human Resources program at Michigan University.

Sol Barer

Dr. Sol J. Barer, Ph.D., is an Independent Director of Aegerion Pharmaceuticals, Inc., since May 2011. Dr. Barer has served as a member of our Board of Directors since May 2011. Dr. Barer is currently the Managing Partner of SJBarer Consulting LLC. He previously served in various positions at Celgene Corporation (a biopharmaceutical company focused on the treatment of cancer and inflammatory diseases), including Chairman and Chief Executive Officer from May 2006 until June 2010, Executive Chairman from June 2010 until December 2010 and Non-Executive Chairman from January 2011 until June 2011. Prior to that, he held several other positions within Celgene, including President and Chief Operating Officer. Dr. Barer joined the Celanese Research Company in 1974 and formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer currently serves on the Boards of Directors of Amicus Therapeutics (a public biopharmaceutical company focused on the development of novel small molecule drugs for the treatment of genetic diseases), InspireMD, Inc. (a public medical device company focused on the development and commercialization of stent system technology), Medgenics (a public gene therapy company), RestorGenex (a public biopharmaceutical company focusing on dermatology, ocular diseases, and women’s health), Teva Pharmaceuticals (a public pharmaceutical company focused on the production of generic medicines, innovative treatments for disorders of the central nervous system, and respiratory products) and several privately held biotechnology companies. Dr. Barer holds a B.S. degree from Brooklyn College and a Ph.D. degree in Organic Chemistry from Rutgers University.

Antonio Gotto

Dr. Antonio M. Gotto, Jr., M.D.,Ph.D is an Independent Director of Aegerion Pharmaceuticals Inc., since January 2006. Dr. Gotto has served as a member of our Board of Directors since January 2006. Dr. Gotto currently serves as Co-Chairman of the Board of Overseers of the Joan and Sanford I. Weill Medical College of Cornell University and Vice President of Cornell University. From January 1997 to December 2011, Dr. Gotto served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University. Previously, Dr. Gotto served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital. Dr. Gotto currently serves as a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences. Dr. Gotto is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association. Dr. Gotto currently serves on the Board of Directors of Esperion Therapeutics (a public biopharmaceutical company focused on the development and commercialization of LDL-C lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers). Dr. Gotto holds a B.A. degree from Vanderbilt University, a D.Phil. degree in Biochemistry from Oxford University in England, where he was a Rhodes Scholar, and an M.D. degree from Vanderbilt University School of Medicine. He completed his residency training at Massachusetts General Hospital in Boston, Massachusetts.

Jorge Plutzky

Dr. Jorge Plutzky, M.D., is an Independent Director of the Company. Dr. Plutzky has served as a member of our Board of Directors since April 2015. Dr. Plutzky is the Director of Preventive Cardiology, which includes the Lipid Clinic, in the Cardiovascular Medicine Division at Brigham and Women’s Hospital. Since 1995, he has been on the faculty at Harvard Medical School and has directed a basic science laboratory focused on transcriptional mechanisms involved in lipid metabolism, adipogenesis and diabetes, and the relationship of these conditions to inflammation and atherosclerosis. Throughout his career, Dr. Plutzky has also been involved in translational clinical studies investigating links between metabolic disorders and cardiovascular disease. Dr. Plutzky has been a member of the Scientific Advisory Committee of the Sarnoff Cardiovascular Research Foundation since 2009 and is now Chair-Elect for this group. Dr. Plutzky has been elected to the American Society for Clinical Investigation and is a Fellow of the American College of Cardiology. Dr. Plutzky’s papers have appeared in journals that include Science, PNAS, Diabetes, Lancet, Annals of Internal Medicine, and Nature Medicine. Dr. Plutzky has been involved with the U.S. Food and Drug Administration, serving both as a member of the Endocrinologic and Metabolic Drugs Advisory Committee and in advising and presenting for new drug application sponsors. He has been involved extensively with both the American Heart Association and the American Diabetes Association. Dr. Plutzky has been recognized with the Eugene Braunwald Teaching Award, the University of Cologne’s Klenk Lecture, Vanderbilt University’s Rabin Lecture, Northwestern University’s DeStevens Lecture, and Harvard Medical School’s Tucker Collins Lecture.Dr. Plutzky holds a B.A. with Highest Honors from the University of Virginia, where he was an Echols Scholar and a member of Phi Beta Kappa, and an M.D. from the University of North Carolina, Chapel Hill.

Paul Thomas

Mr. Paul G. Thomas is Independent Director of Aegerion Pharmaceuticals, Inc., since August 1, 2011. Mr. Thomas has served as a member of our Board of Directors since August 2011. Mr. Thomas is the founder of Roka Bioscience, Inc. (a publicly traded company principally engaged in the development and commercialization of molecular assays for biopharmaceutical processing, food safety and other industrial testing applications), and since September 2009 has served as its Chief Executive Officer. From October 1998 until August 2008, Mr. Thomas served as Chairman, Chief Executive Officer and President of LifeCell Corporation (a publicly traded company that developed and marketed innovative tissue repair products for use in reconstructive, orthopedic and urogynecologic surgical procedures). LifeCell was acquired in 2008 by Kinetic Concepts, Inc. Prior to joining LifeCell, Mr. Thomas was President and Chief Operating Officer of the Pharmaceutical Products Division of Ohmeda Inc. Mr. Thomas is also a member of the Board of Directors of AbioMed, Inc. (a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery). During the past five years, Mr. Thomas has served as a director of Orthovita, Inc. Mr. Thomas holds a B.S. degree in chemistry from St. Michael’s College in Vermont, completed his post-graduate studies in chemistry at the University of Georgia Graduate School of Arts and Science, and received an M.B.A. degree with an emphasis in Marketing and Finance from Columbia University Graduate School of Business.

Anne VanLent

Ms. Anne M. VanLent is Independent Director of Aegerion Pharmaceuticals, Inc., since April 2013. Ms. VanLent has served as a member of our Board of Directors since April 2013. Ms. VanLent is President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent had been Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly traded pharmaceutical company that develops and markets prescription dermatology products, from May 2002 through April 2008. From July 1997 to October 2001, she was the Executive Vice President – Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly-traded biopharmaceutical company. Ms. VanLent currently serves as a director, chair of the Audit Committee, and member of the Nominating and Governance Committee of Biota Pharmaceuticals, Inc.; a director, chair of the Audit Committee, and chair of the Nominating and Governance Committee of Ocera Therapeutics, Inc. (formerly Tranzyme Pharma, Inc.); and a director, chair of the Audit Committee, and member of the Compensation Committee of Onconova Therapeutics, Inc., each a NASDAQ-listed pharmaceuticals company. During the past five years, Ms. VanLent has served as a director of Integra Life Sciences Holdings, Inc., a NASDAQ-listed medical device company, where she served as chair of the Audit Committee from 2006 to 2012, and Penwest Pharmaceuticals Co., a NASDAQ-listed pharmaceuticals company, from 1997 until its sale to Endo Pharmaceuticals in 2010, where she served as chair of the Audit Committee from 2002 until 2010. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College.

Basic Compensation

Name Fiscal Year Total

David Scheer

--

Sandford Smith

--

Gregory Perry

--

Anne Cook

2,258,030

William Andrews

--

Martha Carter

1,520,990

David Aubuchon

--

Mark Sumeray

1,622,110

Mary Weger

1,659,960

Sol Barer

--

Antonio Gotto

--

Jorge Plutzky

--

Paul Thomas

--

Anne VanLent

--
As Of  30 Dec 2014

Options Compensation

Name Options Value

David Scheer

0 0

Sandford Smith

0 0

Gregory Perry

0 0

Anne Cook

0 0

William Andrews

0 0

Martha Carter

5,000 339,851

David Aubuchon

0 0

Mark Sumeray

40,000 2,188,470

Mary Weger

7,000 326,777

Sol Barer

0 0

Antonio Gotto

0 0

Jorge Plutzky

0 0

Paul Thomas

0 0

Anne VanLent

0 0
Search Stocks